Theranostic nanomedicine has shown tremendous promise for more effective and predictive cancer treatment by real-time mornitoring of the delivery of therapeutics to tumors and subsequent therapeutic response. However, the preparation of the theranostic nanoplatforms generally involves complicated procedures to encapsulate the therapeutic and imaging agents into a single nanoformulation. In this work, we develop an innovative nanotheranostic composed of ultrasmall PEG-Bi 2 S 3 nanodots for simultaneous X-ray CT imaging and photothermal therapy. These nanodots possess several unique features: (i) efficient conversion of the NIR light into heat upon laser irradiation; (ii) long circulation time in vivo for effective tumor accumulation; (iii) 100% tumor elimination upon NIR laser irradiation in a tumor xenograft mouse model following systemic injection without obvious side effects; (iv) small size for efficient clearance from the body; and (v) high-performance CT imaging in vivo for potential imaging-guided therapy and the selection of cancer patients with high tumor accumulation. These results strongly suggest that this theranostic nanomedicine may become an effective tool for CT imaging-guided therapy for personalized cancer treatment.
Introduction
Nanotheranostics, which incorporates imaging and therapeutic agents into a single nanoformulation so that the therapy can be monitored noninvasively and in real time, has become a fastgrowing and effective tool in the treatment of various diseases including cancers. 1 To date, enormous efforts have been made to fabricate nanotheranostics by the combination of varieties of imaging models and therapies. [2] [3] [4] [5] [6] Among them, the amalgamation of X-ray CT imaging with photothermal therapy has been considered to be one of most promising strategies for cancer treatment. Compared to other imaging tools, X-ray CT imaging is a widely used imaging tool in clinical diagnosis due to its deep tissue penetration and high resolution. 7, 8 It is capable of providing the whole anatomic information of tumor tissues, including location, size, shape, and detecting if cancer spread has occured. 9, 10 On the other hand, photothermal therapy (PTT) is known to specically treat the tissue of interest in a spatial-, temporal-, and dosage-controlled fashion, with minimal invasiveness. [11] [12] [13] An ideal CT/PTT dual-functional nanomaterials should possess at least the following features: (i) high X-ray attenuation ability; (ii) broad absorbance in the NIR region; (iii) long circulation time in vivo and effective accumulation in the tumor tissues; (iv) good biocompatibility; (v) the nanoparticles by themselves can serve as both imaging and PTT agents for simplifying the synthesis for reproducing; and (vi) robust fabrication processes that are amenable to scale-up for industry translation.
Bismuth sulde (Bi 2 S 3 ) nanostructures hold great promise for CT contrast agents, as Bi possesses larger X-ray attenuation coefficient than iodine, 14 the main CT contrast agent used in clinical imaging. More impressively, Bi 2 S 3 has good biocompatibility and leaves no residue in the organism. 15 Additionally, it is more or less cost effective than currently studied heavy element-based nanoparticulate CT contrasts (e.g. Au, Pt, and Ta). It is also worth noting that Bi 2 S 3 is a semiconductor with an energy gap of 1.33 eV. Such a low energy gap intrinsically enables Bi 2 S 3 to exhibit strong absorbance in the NIR region. 16 Thus, Bi 2 S 3 by itself can serve as a high-performance CT/PTT dual-functional agent without the need of additional combination of other functionalities. Few studies have thus far investigated the photothermal effect of Bi 2 S 3 nanomaterials by themselves or through formation of nanocomposites with other nanomaterials (e.g. graphene and MoS 2 ), [17] [18] [19] [20] and only two of them, to the best of our knowledge, reported the Bi 2 S 3 nanomaterials as CT/PTT agents for cancer treatment. 19, 20 However, Bi 2 S 3 nanomaterials in these two studies have large particle sizes, which will have long retention time in vivo and may not penetrate into the deep tumor tissues, potentially leading to insufficient and heterogeneous hypothermia when the laser irradiation is taken.
Herein, we have developed ultrasmall PEG-Bi 2 S 3 nanodots as a novel CT/PTT agent and systemically investigated their in vivo CT imaging and PTT therapeutic effect. Results demonstrated that PEG-Bi 2 S 3 nanodots have small size, long circulation time in vivo, and high tumor accumulation. Following NIR laser irradiation, PEG-Bi 2 S 3 nanodots efficiently converted the NIR light into heat, leading to hundred percent of tumor elimination and suppressing the tumor reoccurrence, with negligible side effects. In addition, PEG-Bi 2 S 3 nanodots have demonstrated high-performance CT contrast efficacy in vivo, which can be potentially used for real-time and non-invasive tracking the behavior of PEG-Bi 2 S 3 nanodots and identifying the patients who are most likely benet the nanotherapeutics, given the tumor heterogeneity in different patients. We expected that PEG-Bi 2 S 3 nanodots may be used as a simple but powerful theranostic nanoplatform for imaging-guided photothermal therapy for predictive and efficient cancer treatment.
Materials and method

Materials
Oleic acid, oleylamine, octadecance, thioacetamide, and bismuth neodecanoate were purchased from Sigma Aldrich. Poly(vinylpyrrolidone) 8000 was purchased from Alfa Aesar. Iobitridol was purchased from Guerbet (France). All the agents were used without additional purication.
Synthesis of oleic acid-stabilized Bi 2 S 3 nanodots
Oleic acid-stabilized Bi 2 S 3 nanodots were prepared according to previously reported method. 15 In brief, in a typical experiment, bismuth neodecanoate (7.2 g) was dissolved in the solution containing oleic acid (40 mL) and octadecene (80 mL) under vigorous stirring. The mixture was then slowly heated to 165 C and then kept at this temperature for 20 min under Ar protection. Aer cooling down to 105 C, 7 mL of oleyl amine solution containing thioacetamide (0.75 g) was rapidly injected into the mixture under vigorous stirring and Ar protection. The solution immediately turned dark brown upon injection of the thioacetamide. Aer reaction for 1 min, the mixture was allowed to cool down to the room temperature. Thereaer, ethanol was added, and oleic acid-stabilized Bi 2 S 3 nanodots were obtained aer centrifugation and washed twice with ethanol. The isolated oleic acid-stabilized Bi 2 S 3 nanodots were redispersed in chloroform for further modication.
PEGylation of oleic acid-stabilized Bi 2 S 3 nanodots
PEGylation was carried out according to a previously reported method with some modication. 8, 21 In brief, 20 mL DSPE-PEG 2000 dissolved in chloroform (10 mg mL
À1
) was mixed with 10 mL oleic acid-stabilized Bi 2 S 3 nanodots dispersed in chloroform (2 mg mL À1 ) for 10 min under general stirring. Thereaer, the chloroform was evaporated under vacuum at room temperature, followed by slowly heating to 60 C to stabilize the interaction between DSPE-PEG and oleic acid. The resulting PEGcoated Bi 2 S 3 nanodots were then resuspended in 10 mL DI water, sonicated, and ltered using 0.2 mm lter. Aer centrifugation at 10 000 rpm for 20 min, the isolated PEG-coated Bi 2 S 3 nanodots were redispersed in DI water for further characterization.
In vitro cytotoxicity of PEG-coated Bi 2 S 3 nanodots
The cytotoxicity of PEG-coated Bi 2 S 3 nanodots was examined by MTT assay. Briey, 4T1 cells were cultured and seeded in the 96 well plates in RPMI-1640 supplemented with 10% FBS at 37 C in an atmosphere of 5% CO 2 and 95% air. 24 hours later, the medium was replaced by fresh medium containing different concentrations of PEG-coated Bi 2 S 3 nanodots for another 24 hours. The cell variability was then tested by MTT assay.
To further demonstrate the biocompatibility of PEG-coated Bi 2 S 3 nanodots, cell viability of 4T1 cells treated with other PTT agents including CNT, GO, CuS, and CdSe nanoparticles at a concentration of 2 mg mL À1 were also examined using the MTT assay.
Blood biocompatibility of PEG-coated Bi 2 S 3 nanodots
Human complete blood stabilized by EDTA was kindly provided by Second Hospital of Jilin University. 5 mL EDTA-stabilized human complete blood was added into 10 mL PBS, and centrifuged at 9000 rpm for 10 min. Aer washing with PBS ve times, red blood red cells were diluted by 50 mL PBS. Thereaer, 0.4 mL of red blood cell solution was mixed with 1.6 mL of PBS containing different concentrations of PEG-coated Bi 2 S 3 nanodots, PBS alone (negative control), and deionized water (positive control), respectively. Aer incubation at room temperature for 3 hours, the samples were centrifuged at 12 000 rpm for 20 min. The absorbance of the supernatants at the wavelength of 541 nm was examined using a UV-vis spectroscopy. The hemolysis of PEG-coated Bi 2 S 3 nanodots was calculated according to the following equation: hemolysis%
In vitro photothermal conversion performance
To evaluate the photothermal conversion effect of the PEGcoated Bi 2 S 3 nanodots, 1 mL aqueous dispersion of PEGcoated Bi 2 S 3 nanodots at different concentrations (75, 148, 276, and 387 mg mL À1 ) was respectively added in a quartz cuvette and irradiated with an 808 nm NIR laser at a power density of 3 W cm À2 for 500 s. A thermocouple probe with an accuracy of 0.1 C was inserted into the PEG-coated Bi 2 S 3 nanodots aqueous solution perpendicular to the path of the laser. The temperature was recorded every 10 s by a digital thermometer with a thermocouple probe.
Photothermal cytotoxicity
In vitro photothermal cytotoxicity of PEG-coated Bi 2 S 3 nanodots was assessed using 4T1 murine breast cancer cells. Briey, 4T1 cells were cultured in 6-well plates at 37 C for 24 h, and then incubated with PEG-coated Bi 2 S 3 nanodots at a concentration of 75, 150, or 300 mg mL À1 for 30 min. Aer irradiation with an 808 nm laser at a power density of 3 W cm À2 for 5 min, the cells were stained with both calcein AM (calcein acetoxymethyl ester) and PI (propidium iodide), and the cell death was observed using a confocal uorescence microscope.
Tumor xenogra model
Animals were maintained in accordance with the guidelines of the Standardization Administration of the People's Republic of China, and approved by the institutional ethical committee (IEC) of the Second Hospital of Jilin University. For the xenogra tumor models, 4T1 cells were cultured in RPMI-1640 supplemented with 10% FBS at 37 C in an atmosphere of 5% CO 2 and 95% air. 2 Â 10 6 4T1 cells were suspended in 100 mL serum-free culture medium and then inoculated subcutaneously into the bilateral anks of female Balb/C mice. The mice were used for further experiments when the tumor size has achieved to 5 mm in diameter.
In vivo photothermal therapy
For observation of in vivo photothermal therapy effect of PEGcoated Bi 2 S 3 nanodots, 4T1 tumor bearing mice were rst anesthetized by intraperitoneal injection of chloral hydrate solution (10 wt%) and intratumorally injected with 50 mL PEGcoated Bi 2 S 3 nanodots aqueous dispersion (200 mg mL À1 ).
Subsequently, the tumors were irradiated with an 808 nm laser at 3 W cm À2 for 5 min.
For intravenous injection of PEG-coated Bi 2 S 3 nanodots, tumor-bearing mice were injected with PEG-coated Bi 2 S 3 nanodots through the tail vein, and exposed to laser irradiation at 24 h postinjection of PEG-coated Bi 2 S 3 nanodots.
The tumor sizes were measured by a caliper every other day and calculated as the volume according to the following equation:
Tumor volume ¼ (tumor length) Â (tumor width) 2 /2.
Relative tumor volumes were calculated as V/V 0 (V 0 was the tumor volume when the treatment was initiated).
Blood analysis
Healthy mice were intravenously administered with a single dose of PEG-coated Bi 2 S 3 nanodots. Several healthy mice were also used as the control group. The mice were anesthetized and the blood was collected by a cardiac puncture method for blood biochemistry assay.
In vivo CT imaging
Tumor-bearing mice were rst anesthetized by intraperitoneal injection of chloral hydrate solution (10 wt%), and then intravenously injected with PEG-coated Bi 2 S 3 nanodots dispersion in PBS (200 mL, 20 mg Bi per mL) through the tail vein. The whole body CT imaging was performed using clinical CT scanner with the parameters: thickness, 0.9 mm; pitch, 0.99; 120 kVp, 300 mA; eld of view, 350 mm; gantry rotation time, 0.5 s; table speed, 158.9 mm s À1 .
Animal
Characterization
The morphology of PEG-coated Bi 2 S 3 nanodots was characterized by using a TECNAI G2 high-resolution transmission electron microscope and a FEI/Philips XL30 ESEM FEG eld-emission scanning electron microscope. XRD patterns were collected on a D8 ADVANCE (Germany) using Cu Ka (0.15406 nm) radiation.
Results and discussion
Synthesis and characterization of PEG-coated Bi 2 S 3 nanodots
The ultrasmall oleic acid-stabilized Bi 2 S 3 nanodots were synthesized through a "hot injection" method. Briey, the oleylamine solution containing thioacetamide was rapidly injected into the hot octadecance solution containing bismuth neodecanoate and oleic acid at 105 C under vigorous stirring, followed by heating to 165 C and keeping at this temperature for 20 min under Ar protection. Thioacetamide can desulfurize at this temperature and react with bismuth neodecanoate to form Bi 2 S 3 nanodots. The resulting Bi 2 S 3 nanodots can be well dispersed in different organic solvents such as cyclohexane, chloroform, and dichloromethane, and remained stable even aer repeated washing, without any detectable aggregation. In our previous study, we used polyvinylpyrrolidone (PVP) as the exchanging ligand to make the Bi 2 S 3 nanodots water soluble,
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whereas the PVP-modied Bi 2 S 3 nanodots exhibited high viscosity at high concentrations. To address this issue, here we used amphiphilic 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG) for modi-cation of Bi 2 S 3 nanodots through the hydrophobic interaction between DSPE-PEG and oleic acid to reduce the non-specic absorption and thus improve their physiological stability. As shown in Fig. 1a , PEG-coated Bi 2 S 3 nanodots were 3-4 nm in size and well dispersed in water without obvious aggregation. The Bi 2 S 3 crystal structure was conrmed by X-ray powder diffraction (XRD) analysis (Fig. 1b) . In addition, PEG-coated Bi 2 S 3 nanodots showed a linear concentration-dependent increase in the absorbance in the NIR region ( Fig. 1c and d) , suggesting the great potential of PEG-modied Bi 2 S 3 nanodots for NIR-mediated photothermal therapy.
Cytotoxicity of PEG-coated Bi 2 S 3 nanodots
To assess the cytotoxicity of PEG-coated Bi 2 S 3 nanodots, 4T1 cancer cells were incubated with different concentrations of PEG-coated Bi 2 S 3 nanodots for 24 h, and the cell viability was compared to the control cells using MTT assay. As illustrated in Fig. 2a , treatment of PEG-coated Bi 2 S 3 nanodots did not induce obvious toxicity in 4T1 cells at a concentration up to 2 mg mL À1 .
To better demonstrate the potential of PEG-coated Bi 2 S 3 nanodots as a biocompatible PTT agent, we compared the cytotoxicity of PEG-coated Bi 2 S 3 nanodots with several other PTT 
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These results clearly suggested the low cytotoxicity of PEGcoated Bi 2 S 3 nanodots. To further evaluate the biocompatibility of PEG-coated Bi 2 S 3 nanodots, we examined the blood compatibility of PEG-coated Bi 2 S 3 nanodots, which is an important evaluation index to see if the newly developed nanomaterials are applicable for in vivo applications. Similar to the PBS negative control group, no hemolysis was noticed aer incubation of blood with PEGcoated Bi 2 S 3 nanodots, even at a concentration of 2 mg mL À1 , in sharp contrast to the water positive control group, suggesting the good blood compatibility of PEG-coated Bi 2 S 3 nanodots (Fig. S1 †) . All these results strongly suggested that PEG-coated Bi 2 S 3 nanodots can be used as a safe PTT agent for in vivo applications.
Photothermal conversion and photostability
To evaluate the potential of PEG-coated Bi 2 S 3 nanodots in PTT therapy, we rst tested their photothermal conversion capability. PEG-coated Bi 2 S 3 nanodots were dispersed in water at different concentrations, and exposed to an 808 nm laser for 500 seconds at a power density of 3 W cm À2 . The temperature was then monitored. For comparison, the temperature change of pure water was also monitored at the same condition (Fig. 3) . Clearly, the temperature of pure water was increased by less than 3 C aer 500 s of laser irradiation. In contrast, the temperature of PEG-coated Bi 2 S 3 nanodot aqueous solutions showed a dose-dependent increase upon laser irradiation. At a concentration of 276 mg mL À1 , the temperature of PEG-coated Bi 2 S 3 nanodot aqueous solution increased to 34.3 C. Further increase in the concentration of PEG-coated Bi 2 S 3 nanodots did not lead to more enhanced temperature increase, which was presumably due to the saturated nanodots compared to the laser irradiation. More impressively, PEG-coated Bi 2 S 3 nanodots demonstrated excellent photostability: no change in size, morphology, or absorbance in the NIR region was visualized during 1 h continuous laser irradiation ( Fig. S2 and S3 †) . The photothermal conversion efficiency was calculated to be $21% according to previous work (Fig. S3 †) . 24 
In vitro photothermal therapy
The high photothermal conversion of PEG-coated Bi 2 S 3 nanodots makes them feasible to be a PTT agent for cancer therapy. To further demonstrate the photothermal effect of PEG-coated Bi 2 S 3 nanodots, 4T1 cells were incubated with PEG-coated Bi 2 S 3 nanodots and then exposed to laser irradiation with an 808 nm laser at a power density of 3 W cm À2 for 5 min, followed by staining with calcein AM and PI. Cells without treatment or with treatment of lase alone were also stained with calcein AM and PI as the control groups. Fig. 4 demonstrated that nearly no cells died when laser was taken alone, whereas a dosedependent cell death was observed for cells treated with PEGcoated Bi 2 S 3 nanodots, coupled with laser irradiation. Almost all the cells died at a concentration of 300 mg mL À1 aer laser irradiation, which was consistent with the quantitative cell viability analysis (Fig. S4 †) . These results clearly indicated the potential of PEG-coated Bi 2 S 3 nanodots for cancer PTT therapy.
In vivo CT imaging of tumor
Imaging function in theranostics can be used for real-time tracking in vivo pharmacokinetics and biodistribution of therapeutics. One of the advantages of PEG-coated Bi 2 S 3 nanodots compared to currently studied CT/PTT is that PEG-coated Bi 2 S 3 nanodots by themselves can be used as both imaging and therapy, thus simplifying the synthesis. Moreover, superior to Au nanostructures, which also have both imaging and therapeutic functions, Bi is much less expensive than Au, revealing that this strategy had great potential for industrial production.
To examine the in vivo CT imaging performance, PEG-coated Bi 2 S 3 nanodots were then intravenously injected in the mouse and the whole body CT imaging was carried out. Differing from the commercial iodine-based small molecule CT contrast agents, which will be cleared from the blood within seconds to minutes due to their low molecular weights, PEG-coated Bi 2 S 3 nanodots showed prolonged circulation time in the blood. Enhanced CT signals were observed for different organs. There is an increased CT contrast in the heart upon injection, even aer 1 h postinjection (Fig. 5) . The prolonged circulation time will enable PEG-coated Bi 2 S 3 nanodots to accumulate in the tumor through enhanced permeability and retention effect (EPR) effect. It is worth nothing that high CT signal was observed in the bladder, clearly suggesting that Bi 2 S 3 nanodots can be efficiently eliminated from the body through the kidney, due to the small size. The CT value of each organ has been summarized in Table S1 , † which provided further evidence for the CT contrast compared to pre-injection. 4T1 xenogra tumor model was then set up by subcutaneously injection of 4T1 cells suspended in serum-free culture medium into the bilateral anks of healthy Balb/C mice to evaluate if the nanodots are able to accumulate in tumor through the EPR effect. We also quantied the CT values of tumor before vs. aer injection of PEG-coated Bi 2 S 3 nanodots.
At 24 hours postinjection, the CT value of the tumor increased by approximately 3 times, as compared to the CT value of tumor before injection (Fig. 6 ). All these results clearly suggested that PEG-coated Bi 2 S 3 nanodots can be used for imaging-guided therapy and potentially determination of the tumor EPR effect to identify those patients most likely to benet the nanotherapeutics. We also noted that the tumor site become dark aer injection of PEG-coated Bi 2 S 3 nanodots compared to preinjection (Fig. S5 †) , providing further evidence for the accumulation of PEG-coated Bi 2 S 3 nanodots. ICP analysis further conrmed the high accumulation of PEG-coated Bi 2 S 3 nanodots in the tumor site (Fig. S6 †) . Small molecule-based CT contrast agents are known to passage out of tumor due to the small molecule weight. The short retention makes it hard for longterm monitoring the histological analysis of tumor. To better examine the retention effect of our PEG-coated Bi 2 S 3 nanodots, PEG-coated Bi 2 S 3 nanodots were directly injected in the tumor, and the time-dependent CT imaging of tumor was performed. As shown in Fig. 7 , bright CT signal remained even at 30 min postinjection.
In vivo photothermal therapy
Given the excellent photothermal efficiency and effective tumor accumulation and retention, we proceeded to assess the in vivo photothermal therapy effect of PEG-coated Bi 2 S 3 nanodots. PEG-coated Bi 2 S 3 nanodots were injected into 4T1 tumorbearing mice intravenously or intratumorally, and the tumors were irradiated with a 808 nm laser for 5 min at a power density of 3 W cm À2 . As illustrated in Fig. 8a , the tumors were eliminated for mice treated with PEG-coated Bi 2 S 3 nanodots upon laser irradiation, regardless of the injection route. No tumor recurrence was observed (Fig. 8b) . In contrast, the control mice showed fast tumor growth. During one-month period of observation, mice remained healthy, and no abnormalities in eating, drinking, grooming, activity, exploratory behavior, urination, or neurological status were noticed. The body weight of the treated group gradually increased in a manner similar to that of the control groups (Fig. 8c) .
In vivo toxicity studies of PEG-coated Bi 2 S 3 nanodots
Finally, the potential in vivo side effects of PEG-coated Bi 2 S 3 nanodots were also examined. PEG-coated Bi 2 S 3 nanodots were injected into healthy mice at a single dose injection, and the blood was withdrawn for blood analysis. Results showed that the ve important hepatic indicators including aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), total protein (TP) and albumin/globin ratio (A/G) fell within normal ranges and thus revealed no sign of liver injury. Complete blood tests demonstrated no obvious interference with the physiological regulation of haem or triggering the immune responses (Fig. S7 †) .
Conclusions
In this work, we have described an innovative nanotheranostic based on PEG-coated Bi 2 S 3 nanodots with uniform size, good dispersibility in water, and strong NIR absorbance. They have shown long circulation time in vivo and can effectively accumulate in tumor through the EPR effect with long retention time. Upon laser irradiation with an 808 nm laser, PEG-coated Bi 2 S 3 nanodots can efficiently convert the NIR light into heat to generate hyperthermia and thus suppress the tumor growth. In addition, the high X-ray attenuation of Bi enables PEG-coated Bi 2 S 3 nanodots to be a CT contrast agent for potential and realtime tracking the in vivo behavior of PEG-coated Bi 2 S 3 nanodots for theranostic treatment of cancer. We expect PEG-coated Bi 2 S 3 nanodots to provide a new tool for imaging-guided photothermal therapy of various diseases including cancers. 
